Literature DB >> 29374302

[Durvalumab improves prognosis of stage III non-small-cell lung cancer after definitive chemoradiotherapy].

Markus Hecht1, Udo S Gaipl2, Rainer Fietkau2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29374302     DOI： 10.1007/s00066-017-1253-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

2.  Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.

Authors:  Jéssica Ribeiro Gomes; Rafael A Schmerling; Carolina K Haddad; Douglas J Racy; Robson Ferrigno; Erlon Gil; Pedro Zanuncio; Antônio C Buzaid
Journal:  J Immunother       Date:  2016 Nov/Dec       Impact factor: 4.456

3.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

Authors:  Liufu Deng; Hua Liang; Byron Burnette; Michael Beckett; Thomas Darga; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

4.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

5.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.

Authors:  Michael Flentje; Rudolf M Huber; Walburga Engel-Riedel; Stefan Andreas; Jens Kollmeier; Susanne Staar; Nicolas Dickgreber; Nathalie Vaissiere; Cecilia De Almeida; Birgit Edlich; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2016-01-25       Impact factor: 3.621

7.  Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Authors:  Thomas Powles; Peter H O'Donnell; Christophe Massard; Hendrik-Tobias Arkenau; Terence W Friedlander; Christopher J Hoimes; Jae Lyun Lee; Michael Ong; Srikala S Sridhar; Nicholas J Vogelzang; Mayer N Fishman; Jingsong Zhang; Sandy Srinivas; Jigar Parikh; Joyce Antal; Xiaoping Jin; Ashok K Gupta; Yong Ben; Noah M Hahn
Journal:  JAMA Oncol       Date:  2017-09-14       Impact factor: 31.777

8.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

Authors:  Simon J Dovedi; Amy L Adlard; Grazyna Lipowska-Bhalla; Conor McKenna; Sherrie Jones; Eleanor J Cheadle; Ian J Stratford; Edmund Poon; Michelle Morrow; Ross Stewart; Hazel Jones; Robert W Wilkinson; Jamie Honeychurch; Tim M Illidge
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.